You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Non-Perfluoroalkyl and Non-Polyfluoroalkyl Substances (PFAS) Elastomeric Chemical Barrier Materials
SBC: TRITON SYSTEMS, INC. Topic: CBD222001Triton Systems and its partners propose to design and develop a novel chemical barrier elastomer, that does not contain fluorine, for use in CBRN protective ensembles for hazardous materials because current fluorine containing materials are required to be reduced and eventually eliminated for environmental reasons. In Phase I, we will design and fabricate nanocomposite elastomers with enhanced res ...
SBIR Phase I 2023 Department of DefenseOffice for Chemical and Biological Defense -
Artificial Intelligence Tool for Chemical and Biological Plumes Detection
SBC: SPECTRAL SCIENCES INC Topic: CBD202002Accurate and timely detection and classification of chemical and/or biological threat agents (CBA) used by an adversary in a battlefield environment is a crucial task for reconnaissance and force protection systems. A key technology component in CBA plume sensing systems is the light detection and ranging (LIDAR) system. In Phase I a preliminary AI algorithm based on the autoencoding technique was ...
SBIR Phase II 2023 Department of DefenseOffice for Chemical and Biological Defense -
Stable Antimicrobial Formulation of Scopolamine for Multi-dose Vial
SBC: Clear Scientific, LLC Topic: CBD212004Treatment for acute nerve agent poisoning would greatly benefit from the additional use of a scopolamine hydrobromide injectable. However, addition of a single-dose scopolamine injectable to the warfighter kit represents a substantial logistical burden in the field. A multi-dose vial formulation of scopolamine that is effectively antimicrobial and stable in the field would alleviate logistical bur ...
SBIR Phase II 2023 Department of DefenseOffice for Chemical and Biological Defense -
FRAMER: Fast Reconstruction of Architectural Models from Existing Resources
SBC: FTL LABS CORP Topic: CBD222005FTL Labs Corporation, together with collaborators at the National Institute of Standards and Technology and University of Massachusetts professor Dr. Evangelos Kalogerakis, proposes a powerful new system for automatic 3D building model synthesis. FTL's “FRAMER” (Fast Reconstruction of Architectural Models from Existing Resources) system is designed to be flexible, fast, and accurate. It combin ...
SBIR Phase I 2023 Department of DefenseOffice for Chemical and Biological Defense -
AI-Assisted Clutter Mitigation for Standoff LIDAR Plume Detection
SBC: PHYSICAL SCIENCES INC. Topic: CBD202002Physical Sciences Inc. proposes to mature a suite of artificial intelligence algorithms developed to discriminate airborne chemical/biological warfare agent plumes from battlefield clutter in standoff light detection and ranging (LIDAR) data. The AI-assisted LIDAR clutter mitigation (ALCM) system tracks all plume-type objects within the LIDAR field of regard, and employs a two-stage classification ...
SBIR Phase II 2022 Department of DefenseOffice for Chemical and Biological Defense -
Stable Antimicrobial Formulation of Scopolamine for Multi-dose Vial
SBC: Clear Scientific, LLC Topic: CBD212004Recent efforts to improve treatment for nerve agent poisoning include the development of a scopolamine hydrobromide injectable as an anticholinergic. A scopolamine injectable would add an extremely beneficial capability to the warfighter kit, however, incorporation of single-use vials represents a substantial logistical burden in the field. Co-formulation of the scopolamine injectable with a suita ...
SBIR Phase I 2022 Department of DefenseOffice for Chemical and Biological Defense -
Roll-to-Roll Development of Surface-Enhanced Raman Scattering Substrates
SBC: MICROCONTINUUM, INC. Topic: CBD213001Because of its high specificity, Raman spectroscopy has proven to be a reliable, field-deployable detection technique for assessing chemical threats such as chemical warfare and biological agents, energetic materials, and illicit narcotics. DOD and DHS utilize various portable Raman systems in sensitive site exploitation, checkpoint scenarios, and for screening potential hazardous content on surfa ...
SBIR Phase I 2022 Department of DefenseOffice for Chemical and Biological Defense -
Portable Atmospheric Plasma Decontamination
SBC: TRITON SYSTEMS, INC. Topic: CBD203003In order to limit the spread of contamination and restore combat operations, CBBD is requesting the development of a man-portable system that rapidly decontaminates items, such as sensitive equipment, etc. The decontamination system will be effective against a broad spectrum of biological agents (spores, bacteria, and virus) within minutes. The decontamination efficacy should be 99.9 percent reduc ...
SBIR Phase II 2022 Department of DefenseOffice for Chemical and Biological Defense -
Gauze indicated for the treatment of wounds in presence of chemical threats
SBC: Nano Terra, Inc. Topic: CBD161003Wounds sustained in a chemically contaminated environment are uniquely challenging to treat. Current methods include irrigation with water or a lavage solution and packing with standard gauze. These methods fail to detoxify any chemical warfare agent (CWA) present on the wound and result in a contaminated “hot” gauze which complicates safety and environmental considerations for the patient and ...
SBIR Phase II 2022 Department of DefenseOffice for Chemical and Biological Defense -
Dual Formulation of Atropine/Scopolamine with Enhanced Stability
SBC: Clear Scientific, LLC Topic: CBD181005The current US military standard-of-care for organophosphorus nerve agent poisoning is the application of atropine sulfate and 2-pralidoxime autoinjectors, targeting the reversal of acetylcholinesterase enzyme inhibition (via 2-PAM) and the management of OPNA symptoms (via atropine). However, atropine efficacy is largely limited to the periphery and its inability to pass the blood brain barrier an ...
SBIR Phase II 2022 Department of DefenseOffice for Chemical and Biological Defense